These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Cilostazol Effect on Amikacin-Induced Ototoxicity: An Experimental Study.
    Author: El-Anwar MW, Abdelmonem S, Nada E, Galhoom D, Abdelsameea AA.
    Journal: Audiol Neurootol; 2016; 21(4):250-253. PubMed ID: 27576862.
    Abstract:
    OBJECTIVES: To find out the possible protective effect of cilostazol against amikacin-induced ototoxicity. METHODS: This study was carried out on 24 adult male rats classified into 4 equal groups of 6 animals each. (1) The control group was administered saline (1 ml/day, p.o.) for 14 days. (2) The amikacin group was administered amikacin (200 mg/kg, i.m.) once daily for 14 days. (3) The cilostazol-amikacin (14 days) group was administered cilostazol (30 mg/kg, p.o.) once daily and amikacin (200 mg/kg, i.m.) once daily for 14 days. (4) The cilostazol (28 days)-amikacin (14 days) group was administered cilostazol (30 mg/kg, p.o.) once daily for 28 days and amikacin (200 mg/kg, i.m.) once daily for 14 days. Changes in the transient evoked otoacoustic emissions (TEOAEs) in the 4 groups were interpreted statistically. RESULTS: No reported significant differences in TEOAE levels were detected between the groups at the start of the study. In all frequency bands, TEOAEs disappeared after amikacin treatment in the amikacin-alone group and remained absent in the amikacin-cilostazol (14 days) group, while TEOAEs reappeared in the amikacin-cilostazol (28 days) group. CONCLUSION: Cilostazol treatment for 28 days had a protective effect against amikacin-induced ototoxicity in rats.
    [Abstract] [Full Text] [Related] [New Search]